Results 31 to 40 of about 128,993 (222)

Biosimilar ranibizumab (BS1) – early experience from Japan (BRIJ study) [PDF]

open access: yes
Anti-vascular endothelial growth factor (VEGF) injections are the mainstay of treatment for retinal vascular diseases. However, despite their efficacy, the cost of long term intravitreal injections poses a significant burden on patients and healthcare ...
Rezaei, Kourous A.   +126 more
core   +3 more sources

Biosimilar Agents for Psoriasis Treatment: The Perspective of Portuguese Patients

open access: yesActa Médica Portuguesa, 2018
Introduction: Biosimilars are highly similar copies of previously approved original biologic medicines. Their introduction on the market may yield cost reduction.
Alexandra Azevedo   +3 more
doaj   +1 more source

Biosimilar tenecteplase versus alteplase in acute ischemic stroke: A real world study

open access: yesAnnals of Indian Academy of Neurology, 2023
Background and Purpose: There is an unmet need for a more effective thrombolytic agent in acute ischemic stroke (AIS) management. Various studies and meta-analysis suggest tenecteplase (TNK) as non-inferior over alteplase (rTPA).
Ayush Mohan   +11 more
doaj   +1 more source

Medicines under additional monitoring in the European Union [PDF]

open access: yesFarmacia Hospitalaria, 2019
Objective: The objective of this study was to analyse the characteristics of medicines subject to additional monitoring. We assessed the following aspects: the criteria applied to approve a medicine as being subject to additional monitoring; the ...
Esther Salgueiro   +5 more
doaj   +1 more source

Launching biosimilar rituximab: an industry opinion on biosimilar uptake in Europe

open access: yes, 2017
Richard Trollope and Sue Johnson talk with Henry Ireland, Senior Editor about the recent approval of biosimilar rituximab (Truxima®) & the current state of biosimilar uptake across Europe Richard Trollope, Head of Biosimilars, Mundipharma ...
Henry Ireland   +2 more
core   +1 more source

Statistical assessment of biosimilar products

open access: yes, 2009
[[abstract]]Biological products or medicines are therapeutic agents that are produced using a living system or organism. Access to these life-saving biological products is limited because of their expensive costs. Patents on the early biological products
Chow, SC;Liu, JP   +2 more
core   +1 more source

Switching from Biosimilar to Biosimilar Adalimumab, Including Multiple Switching, in Crohn's Disease: A Prospective Study [PDF]

open access: yes, 2021
No data are available regarding the safety and effectiveness of the biosimilar-to-biosimilar switch of adalimumab in any disease, and in particular in Crohn’s disease (CD).
Vernero, Marta   +16 more
core   +1 more source

Biosimilar medicines and cost-effectiveness

open access: yes, 2011
Steven SimoensResearch Centre for Pharmaceutical Care and Pharmaco-economics, Faculty of Pharmaceutical Sciences, Katholieke Universiteit Leuven, Leuven, BelgiumAbstract: Given that biosimilars are agents that are similar but not identical to the ...
Steven Simoens
core   +1 more source

Biosimilar uptake in the United States: Examining state-level longitudinal trends in biosimilar filgrastim use and their association with biosimilar substitution policies [PDF]

open access: yes, 2020
Thesis (Ph.D.)--University of Washington, 2020Defined as medicines manufactured in a living system, biologics have demonstrated high clinical utility for an array of therapeutic areas.
Grewal, Simrun Kaur
core  

Revisión de dosieres de heparina y enoxaparina: incumplimiento de la normativa de Costa Rica para el registro sanitario de biosimilares farmacéuticos

open access: yesArs Pharmaceutica
RESUMEN Objetivo: Determinar los aspectos esenciales de la reglamentación de Costa Rica referente al registro sanitario de biosimilares y compararlos con la información brindada en los dosieres de laboratorios fabricantes de heparina y enoxaparina ...
Rebeca Álvarez Brenes   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy